| Literature DB >> 30584365 |
Piotr Małczak1,2, Grzegorz Torbicz1, Mateusz Rubinkiewicz1, Natalia Gajewska1, Nadia Sajuk1, Kamil Rozmus1, Michał Wysocki1,2, Piotr Major1,2, Andrzej Budzyński1,2, Michał Pędziwiatr1,2.
Abstract
INTRODUCTION: Gastric cancer is a worldwide health concern, being one of the five most common malignant neoplasms worldwide. Currently, an open approach is the gold standard for surgical treatment. Incorporation of laparoscopy as a method of choice for gastric resections remains controversial because of limited evidence of eligibility. To date, there are no high-quality randomized quality trials on totally laparoscopic D2 total gastrectomies. AIM: The aim of this study was to assess currently available literature and provide meta-analysis on acquired data regarding short-term outcomes with a subgroup analysis of western and eastern studies.Entities:
Keywords: laparoscopy; meta-analysis; systematic review; total gastrectomy
Year: 2018 PMID: 30584365 PMCID: PMC6289212 DOI: 10.2147/CMAR.S182557
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.989
Figure 1PRISMA flowchart.
Baseline characteristics of included studies
| First author | Year | Study type | Country | N, lap/open | F/M | Mean age, lap/open | Tumor size, lap | Tumor size, open | T stage, lap | T stage, open | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dulucq | 2005 | C | France | 8/11 | 11/8 | 75/67 | 5.5 | 6.1 | 7 | ||
| Topal | 2008 | C | Belgium | 38/22 | 20/40 | 68/69 | 4.7 | 3.0 | I 17, II 7, III 10, IV 4 | I 7, II 7, III 6, IV 2 | 4 |
| Kim | 2013 | C | Korea | 139/207 | 126/220 | 58/56 | 3.2 | 4.0 | I 107, II 213, III 15, IV 4 | I 128, II 34, III 37, IV 8 | 9 |
| Lu | 2015 | C | China | 252/252 | 83/421 | ND | ND | ND | I 52, II 56, III 144 | I 56, II 45, III 151 | 9 |
| Ramagen | 2015 | CC | Brazil | 47/64 | 34/77 | 57.8/59.7 | ND | ND | I 14,II 13, III 20 | I 21, II 16, III 27 | 5 |
| Lu | 2016 | CC | China | 61/61 | 46/76 | 59/57 | ND | ND | I 18, II 17, III 26 | I 18, II 19, III 24 | 8 |
| Shu | 2016 | CC | China | 136/136 | 94/178 | 65/64 | ND | ND | I 38, II 98 | I 39, II 97 | 9 |
| Wu | 2016 | CC | China | 74/74 | 45/103 | 62/60 | ND | ND | I 14, II 60 | I 12, II 62 | 9 |
Abbreviations: C, cohort; CC, case-control; F/M, female/male; ND, no data; NOS, Newcastle–Ottawa Scale.
Figure 2Tumor stage distribution among groups.
Figure 3Operative time analysis.
Figure 4Morbidity analysis.
Figure 5Anastomotic leakage analysis.
Figure 6Surgical site infection analysis.
Figure 7Cardiac complications analysis.
Figure 8Pulmonary complications analysis.
Figure 9Length of hospital stay analysis.
Figure 10R0 rate analysis.
Figure 11Harvested lymph nodes analysis.